Related Experiment Video
Updated: Jan 14, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Comparative analysis of reovirus replication efficiency in HEK293T, L929, and huh-7 cell lines: implications for
Reihaneh Kazemi1, Mojtaba Hamidi-Fard2, Elham Siasi1
1Department of Genetics, NT.C., Islamic Azad University, Tehran, Iran.
Abstract:
Oncolytic viruses, such as reovirus, represent a transformative approach in cancer therapy by selectively targeting malignant cells through mechanisms like RAS pathway activation. While clinical trials have demonstrated the safety and efficacy of reovirus in combination therapies, efficient large-scale production remains a critical challenge. Optimal cell lines for maximizing reovirus replication are essential for scalable manufacturing but remain understudied. This study evaluates reovirus propagation in HEK293T, L929, and Huh-7 cell lines to identify the most effective platform for large-scale production. Reovirus replication and cytotoxicity were assessed using plaque assays, trypan blue viability staining, real-time PCR, and MTT assays. Cell lines were infected at a MOI of 10, with samples collected at 0, 24, 48, and 72 h post-infection. HEK293T cells showed the strongest cytopathic effects after reovirus infection compared to L929 and Huh-7 cells. Trypan blue staining confirmed reduced viability in HEK293T cells. Plaque assays indicated higher viral replication in these cells. Real-time PCR revealed increased viral RNA levels in HEK293T samples. MTT assays demonstrated decreased metabolic activity, reflecting greater virus-induced toxicity. HEK293T cells emerge as the optimal platform for reovirus production due to their robust replication capacity and pronounced cytotoxicity, key attributes for oncolytic therapy applications. This study underscores HEK293T's potential to meet the increasing demand for scalable oncolytic virus manufacturing, paving the way for enhanced therapeutic applications in cancer treatment.
Insights
HEK293T cells are the best for producing oncolytic reovirus, showing superior replication and cancer cell killing. This finding supports scalable manufacturing for advanced cancer therapies.
Area of Science:
- Oncolytic virotherapy
- Cancer therapeutics
- Viral manufacturing
Background:
- Oncolytic viruses, like reovirus, offer a promising cancer treatment strategy.
- Efficient large-scale production of oncolytic viruses is crucial but challenging.
- Identifying optimal cell lines for virus propagation is key for manufacturing.
Purpose of the Study:
- To evaluate reovirus propagation in HEK293T, L929, and Huh-7 cell lines.
- To identify the most effective cell line for scalable oncolytic reovirus production.
- To assess reovirus replication and cytotoxicity in different cell lines.
Main Methods:
- Infection of cell lines (HEK293T, L929, Huh-7) with reovirus at MOI 10.
- Assessment of viral replication using plaque assays and real-time PCR.
- Evaluation of cytotoxicity via trypan blue viability staining and MTT assays.
Main Results:
- HEK293T cells exhibited the most significant cytopathic effects and reduced viability post-infection.
- Plaque assays and real-time PCR confirmed higher reovirus replication in HEK293T cells.
- MTT assays indicated greater virus-induced metabolic activity reduction in HEK293T cells.
Conclusions:
- HEK293T cells are the optimal platform for oncolytic reovirus production due to high replication and cytotoxicity.
- This finding facilitates scalable manufacturing to meet the demand for oncolytic virus therapies.
- HEK293T cells support enhanced therapeutic applications in cancer treatment.
